The purpose of this study is to compare how these two treatments affect quality of life, safety, and costs one year after the treatment. The study will look at which treatment works better for children with cerebral palsy who cannot walk and have problems with muscle stiffness. Both treatments aim to help reduce the muscle stiffness that makes movement difficult and affects daily activities.

During the study, children will receive either the baclofen pump or the surgical procedure. The study will follow participants for one year after treatment to measure various outcomes. These include changes in quality of life, any side effects or problems that occur, muscle stiffness levels, movement ability, communication, sleep, and other health factors. The study will also track how much medication is being used and whether the treatments help achieve the goals set for each child. Information about costs related to healthcare will also be collected to understand which treatment provides better value.

Children taking part in this study will receive either cenegermin or placebo through an intranasal delivery device, which is a special tool designed to deliver the treatment inside the nose. The study is designed as a crossover study, which means that children will receive both the active treatment and placebo at different times during the study. The treatment period will last up to 28 days. Throughout the study, doctors will monitor the children closely to check for any unwanted effects and to see how the treatment affects their condition.

During the study, doctors will measure several things including any side effects that occur, changes in muscle stiffness using a scoring system, changes in movement abilities, daily activities, social and thinking skills, and communication function. Blood samples will be taken to measure the amount of nerve growth factor in the blood. The study will also include regular checks such as vital signs, weight and height measurements, physical examinations, laboratory tests, and tests to monitor heart and brain activity. Children participating in the study should continue their regular physical therapy or occupational therapy throughout the study period.

The purpose of the study is to assess the long-term effectiveness of these treatments over a period of 15 months. Participants will receive either the Botox injections or the Scopoderm patches, along with a standardized rehabilitation guidance. The study will monitor the degree and impact of drooling at various intervals, including 1, 3, 6, 9, 12, and 15 months, to determine how well each treatment works in reducing drooling.

Throughout the study, researchers will also observe any side effects or complications that may arise from the treatments. This includes tracking the number of hospitalizations due to drooling-related issues, the use of antibiotics for infections, and any adverse events experienced by the participants. The study aims to provide valuable insights into the most effective treatment for managing drooling in children with cerebral palsy.

Participants in the study will receive a single injection of NT 201 or a placebo. The study will compare the effects of NT 201 to the placebo over a period of several weeks. The main goal is to see if NT 201 can improve muscle stiffness in the legs of children and adolescents with cerebral palsy between the fourth and sixth week after the injection. The study will also include an open-label extension period, where all participants may receive NT 201, to further assess its long-term effects.

The study is designed to be prospective, meaning it looks forward in time, and randomized, which means participants are randomly assigned to receive either NT 201 or a placebo. It is also double-blind, so neither the participants nor the researchers know who is receiving the actual treatment or the placebo during the initial phase. This helps ensure that the results are unbiased. The study will take place in multiple centers, allowing for a diverse group of participants to be involved.

The purpose of the study is to assess how effective and safe Valbenazine is in treating dyskinesia in both children and adults with cerebral palsy. Participants in the study will be randomly assigned to receive either Valbenazine or a matching placebo, which looks like the medication but does not contain the active ingredient. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, participants will take the medication or placebo for a set period, and their progress will be monitored by healthcare professionals. The study aims to observe changes in the severity of involuntary movements and overall improvement in the condition. The trial will also evaluate the safety and tolerability of Valbenazine, ensuring that it is safe for use in treating dyskinesia due to cerebral palsy.